Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes
- PMID: 20071685
- DOI: 10.1093/jnci/djp482
Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes
Abstract
Background: The National Institutes of Health Office of Medical Applications of Research commissioned a structured literature review on the incidence, treatment, and outcomes of ductal carcinoma in situ (DCIS) as a background article for the State of the Science Conference on Diagnosis and Management of DCIS.
Methods: Published studies were identified and abstracted from MEDLINE and other sources. We include articles published between 1965 and January 31, 2009; 374 publications were identified that addressed DCIS incidence, staging, treatment, and outcomes in adult women.
Results: In the United States, DCIS incidence rose from 1.87 per 100 000 in 1973-1975 to 32.5 in 2004. Incidence increased in all ages but more so in women older than 50 years. Increased use of mammography explains some but not all of the increased incidence. Risk factors for incident DCIS include older age and family history. Although tamoxifen treatment prevented both invasive breast cancer and DCIS, raloxifene treatment decreased incidence of invasive breast cancer but not DCIS. Among patients with DCIS, magnetic resonance imaging was more sensitive than mammography for detecting multicentric disease and estimating tumor size. Because about 15% of patients with DCIS identified on core needle biopsy are diagnosed with invasive breast cancer after excision or mastectomy, the accuracy of sentinel lymph node biopsy after excision is relevant to surgical management of DCIS. Most studies demonstrated that sentinel lymph node biopsy is feasible after breast-conserving surgery (BCS). Younger age, positive surgical margins, tumor size and grade, and comedo necrosis were consistently related to DCIS recurrence. DCIS outcomes after either mastectomy or BCS plus radiation therapy were superior to BCS alone. Tamoxifen treatment after DCIS diagnosis reduced risk of recurrent disease.
Conclusions: Scientific questions deserving further investigation include the relationship between mammography use and DCIS incidence and whether imaging technologies and treatment guidelines can be modified to focus on lesions that are most likely to become clinically problematic.
Similar articles
-
Post-operative radiotherapy for ductal carcinoma in situ of the breast.Cochrane Database Syst Rev. 2009 Jul 8;(3):CD000563. doi: 10.1002/14651858.CD000563.pub5. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2009 Oct 07;(4):CD000563. doi: 10.1002/14651858.CD000563.pub6. PMID: 19588320 Updated.
-
Post-operative radiotherapy for ductal carcinoma in situ of the breast.Cochrane Database Syst Rev. 2009 Oct 7;(4):CD000563. doi: 10.1002/14651858.CD000563.pub6. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2013 Nov 21;(11):CD000563. doi: 10.1002/14651858.CD000563.pub7. PMID: 19821272 Updated.
-
The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.Health Technol Assess. 2011 Sep;15(34):v-vi, 1-322. doi: 10.3310/hta15340. Health Technol Assess. 2011. PMID: 21951942 Free PMC article.
-
Post-operative radiotherapy for ductal carcinoma in situ of the breast.Cochrane Database Syst Rev. 2009 Jan 21;(1):CD000563. doi: 10.1002/14651858.CD000563.pub4. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2009 Jul 08;(3):CD000563. doi: 10.1002/14651858.CD000563.pub5. PMID: 19160183 Updated.
-
Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.Breast Cancer Res Treat. 2018 Feb;167(3):751-759. doi: 10.1007/s10549-017-4553-5. Epub 2017 Oct 28. Breast Cancer Res Treat. 2018. PMID: 29079937
Cited by
-
Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment.JCO Oncol Pract. 2021 Nov;17(11):e1639-e1648. doi: 10.1200/OP.20.00614. Epub 2021 Mar 12. JCO Oncol Pract. 2021. PMID: 33710917 Free PMC article.
-
MRI of the breast in patients with DCIS to exclude the presence of invasive disease.Eur Radiol. 2012 Jul;22(7):1504-11. doi: 10.1007/s00330-012-2394-5. Epub 2012 Feb 26. Eur Radiol. 2012. PMID: 22367470
-
Biology, treatment, and outcome in very young and older women with DCIS.Ann Surg Oncol. 2012 Nov;19(12):3777-84. doi: 10.1245/s10434-012-2413-4. Epub 2012 May 24. Ann Surg Oncol. 2012. PMID: 22622473 Free PMC article. Clinical Trial.
-
Vav2 protein overexpression marks and may predict the aggressive subtype of ductal carcinoma in situ.Biomark Res. 2014 Nov 28;2:22. doi: 10.1186/2050-7771-2-22. eCollection 2014. Biomark Res. 2014. PMID: 25785189 Free PMC article.
-
Comparative Effectiveness of Surgical Options for Patients with Ductal Carcinoma In Situ: An Instrumental Variable Approach.Perm J. 2018;22:17-132. doi: 10.7812/TPP/17-132. Perm J. 2018. PMID: 30028673 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical